Antitumor activity of a new orally active organotin compound: A preliminary study in murine tumor models

Federica Barbieri, Maurizio Viale, Fabio Sparatore, Gennaro Schettini, Anna Favre, Cristina Bruzzo, Federica Novelli, Angela Alama

Research output: Contribution to journalArticle

Abstract

The toxicity and antitumor activity of the novel organotin compound triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), administered by the oral route, have been evaluated against three transplantable murine tumor models: P388 lymphocytic leukemia, B16F10 melanoma and 3LL Lewis lung carcinoma. Mild and reversible signs of acute toxicity such as behavioral symptoms, weight loss and histological alterations were mainly reported at the highest single dose of 28 mg/kg. Conversely, lower concentrations of compound ranging from 7 to 21 mg/kg did not result in major toxic effects, even after repeated dosing. The antitumor activity studies showed that fractionation dosing, rather than single bolus administration, over 1 week, might prove more active and better tolerated by allowing the achievement of the highest therapeutic total dose of IST-FS 29 (42 mg/kg). Indeed, repeated administrations of IST-FS 29 resulted in marked significant improvement of antitumor activity against B16F10 (50% of tumor volume inhibition, p = 0.0003) and, to a greater extent, 3LL (90% of tumor volume inhibition, p = 0.0001) tumors. These results indicate that IST-FS 29 might be a suitable candidate as an orally administrable anticancer drug and support its further development in human tumor xenografts.

Original languageEnglish
Pages (from-to)599-604
Number of pages6
JournalAnti-Cancer Drugs
Volume13
Issue number6
DOIs
Publication statusPublished - 2002

Fingerprint

Organotin Compounds
Tumor Burden
Neoplasms
Lewis Lung Carcinoma
Lymphoid Leukemia
Behavioral Symptoms
Poisons
Human Development
Heterografts
Weight Loss
Melanoma
IST-FS 29
Pharmaceutical Preparations

Keywords

  • IST-FS 29
  • Murine tumor models
  • Organotin
  • Triethyltin(IV)lupinylsulfide hydrochloride

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Antitumor activity of a new orally active organotin compound : A preliminary study in murine tumor models. / Barbieri, Federica; Viale, Maurizio; Sparatore, Fabio; Schettini, Gennaro; Favre, Anna; Bruzzo, Cristina; Novelli, Federica; Alama, Angela.

In: Anti-Cancer Drugs, Vol. 13, No. 6, 2002, p. 599-604.

Research output: Contribution to journalArticle

Barbieri, Federica ; Viale, Maurizio ; Sparatore, Fabio ; Schettini, Gennaro ; Favre, Anna ; Bruzzo, Cristina ; Novelli, Federica ; Alama, Angela. / Antitumor activity of a new orally active organotin compound : A preliminary study in murine tumor models. In: Anti-Cancer Drugs. 2002 ; Vol. 13, No. 6. pp. 599-604.
@article{6964dabb50f84287b2949a35ac07f234,
title = "Antitumor activity of a new orally active organotin compound: A preliminary study in murine tumor models",
abstract = "The toxicity and antitumor activity of the novel organotin compound triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), administered by the oral route, have been evaluated against three transplantable murine tumor models: P388 lymphocytic leukemia, B16F10 melanoma and 3LL Lewis lung carcinoma. Mild and reversible signs of acute toxicity such as behavioral symptoms, weight loss and histological alterations were mainly reported at the highest single dose of 28 mg/kg. Conversely, lower concentrations of compound ranging from 7 to 21 mg/kg did not result in major toxic effects, even after repeated dosing. The antitumor activity studies showed that fractionation dosing, rather than single bolus administration, over 1 week, might prove more active and better tolerated by allowing the achievement of the highest therapeutic total dose of IST-FS 29 (42 mg/kg). Indeed, repeated administrations of IST-FS 29 resulted in marked significant improvement of antitumor activity against B16F10 (50{\%} of tumor volume inhibition, p = 0.0003) and, to a greater extent, 3LL (90{\%} of tumor volume inhibition, p = 0.0001) tumors. These results indicate that IST-FS 29 might be a suitable candidate as an orally administrable anticancer drug and support its further development in human tumor xenografts.",
keywords = "IST-FS 29, Murine tumor models, Organotin, Triethyltin(IV)lupinylsulfide hydrochloride",
author = "Federica Barbieri and Maurizio Viale and Fabio Sparatore and Gennaro Schettini and Anna Favre and Cristina Bruzzo and Federica Novelli and Angela Alama",
year = "2002",
doi = "10.1097/00001813-200207000-00006",
language = "English",
volume = "13",
pages = "599--604",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Antitumor activity of a new orally active organotin compound

T2 - A preliminary study in murine tumor models

AU - Barbieri, Federica

AU - Viale, Maurizio

AU - Sparatore, Fabio

AU - Schettini, Gennaro

AU - Favre, Anna

AU - Bruzzo, Cristina

AU - Novelli, Federica

AU - Alama, Angela

PY - 2002

Y1 - 2002

N2 - The toxicity and antitumor activity of the novel organotin compound triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), administered by the oral route, have been evaluated against three transplantable murine tumor models: P388 lymphocytic leukemia, B16F10 melanoma and 3LL Lewis lung carcinoma. Mild and reversible signs of acute toxicity such as behavioral symptoms, weight loss and histological alterations were mainly reported at the highest single dose of 28 mg/kg. Conversely, lower concentrations of compound ranging from 7 to 21 mg/kg did not result in major toxic effects, even after repeated dosing. The antitumor activity studies showed that fractionation dosing, rather than single bolus administration, over 1 week, might prove more active and better tolerated by allowing the achievement of the highest therapeutic total dose of IST-FS 29 (42 mg/kg). Indeed, repeated administrations of IST-FS 29 resulted in marked significant improvement of antitumor activity against B16F10 (50% of tumor volume inhibition, p = 0.0003) and, to a greater extent, 3LL (90% of tumor volume inhibition, p = 0.0001) tumors. These results indicate that IST-FS 29 might be a suitable candidate as an orally administrable anticancer drug and support its further development in human tumor xenografts.

AB - The toxicity and antitumor activity of the novel organotin compound triethyltin(IV)lupinylsulfide hydrochloride (IST-FS 29), administered by the oral route, have been evaluated against three transplantable murine tumor models: P388 lymphocytic leukemia, B16F10 melanoma and 3LL Lewis lung carcinoma. Mild and reversible signs of acute toxicity such as behavioral symptoms, weight loss and histological alterations were mainly reported at the highest single dose of 28 mg/kg. Conversely, lower concentrations of compound ranging from 7 to 21 mg/kg did not result in major toxic effects, even after repeated dosing. The antitumor activity studies showed that fractionation dosing, rather than single bolus administration, over 1 week, might prove more active and better tolerated by allowing the achievement of the highest therapeutic total dose of IST-FS 29 (42 mg/kg). Indeed, repeated administrations of IST-FS 29 resulted in marked significant improvement of antitumor activity against B16F10 (50% of tumor volume inhibition, p = 0.0003) and, to a greater extent, 3LL (90% of tumor volume inhibition, p = 0.0001) tumors. These results indicate that IST-FS 29 might be a suitable candidate as an orally administrable anticancer drug and support its further development in human tumor xenografts.

KW - IST-FS 29

KW - Murine tumor models

KW - Organotin

KW - Triethyltin(IV)lupinylsulfide hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=0036021019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021019&partnerID=8YFLogxK

U2 - 10.1097/00001813-200207000-00006

DO - 10.1097/00001813-200207000-00006

M3 - Article

C2 - 12172505

AN - SCOPUS:0036021019

VL - 13

SP - 599

EP - 604

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 6

ER -